Review



oehr optum electronic health records  (Optum Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Optum Inc oehr optum electronic health records
    Oehr Optum Electronic Health Records, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oehr/electronic+health+records/pm41935054-237-50-51
    Average 86 stars, based on 1 article reviews
    oehr optum electronic health records - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
    Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).



    Similar Products

    oehr optum electronic health records  (Optum Inc)
    86
    Optum Inc oehr optum electronic health records
    Oehr Optum Electronic Health Records, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oehr/electronic+health+records/pm41935054-237-50-51
    Average 86 stars, based on 1 article reviews
    oehr optum electronic health records - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    de-identified electronic health record dataset oehr  (Optum Inc)
    90
    Optum Inc de-identified electronic health record dataset oehr
    De Identified Electronic Health Record Dataset Oehr, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oehr/de+identified+electronic+health+record+dataset+oehr/pmc10871374__media___1-125-2-7
    Average 90 stars, based on 1 article reviews
    de-identified electronic health record dataset oehr - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    oehr  (Optum Inc)
    90
    Optum Inc oehr
    Description of databases from the Observational Health Data Sciences and Informatics network included in the study.
    Oehr, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oehr/oehr/pmc10565313-196-14-18
    Average 90 stars, based on 1 article reviews
    oehr - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    optuminsights electronic health record (oehr) database  (Humedica Inc)
    90
    Humedica Inc optuminsights electronic health record (oehr) database
    Description of databases from the Observational Health Data Sciences and Informatics network included in the study.
    Optuminsights Electronic Health Record (Oehr) Database, supplied by Humedica Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oehr/optuminsights+electronic+health+record++oehr++database/pm31054973-66-0-7
    Average 90 stars, based on 1 article reviews
    optuminsights electronic health record (oehr) database - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Description of databases from the Observational Health Data Sciences and Informatics network included in the study.

    Journal: BMJ Medicine

    Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

    doi: 10.1136/bmjmed-2023-000651

    Figure Lengend Snippet: Description of databases from the Observational Health Data Sciences and Informatics network included in the study.

    Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

    Techniques:

    Proportional incident use of second line antihyperglycaemic drugs in United States national databases, United States health system. CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; DPP-4i=dipeptidyl peptidase-4 inhibitors; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; JHM=Johns Hopkins Medicine; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart-Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; SU=sulfonylurea; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Journal: BMJ Medicine

    Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

    doi: 10.1136/bmjmed-2023-000651

    Figure Lengend Snippet: Proportional incident use of second line antihyperglycaemic drugs in United States national databases, United States health system. CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; DPP-4i=dipeptidyl peptidase-4 inhibitors; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; JHM=Johns Hopkins Medicine; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart-Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; SU=sulfonylurea; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

    Techniques:

    Proportional first incident use of glucagon-like peptide-1 receptor agonists as second line therapy after metformin in patients with established cardiovascular disease, and patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Center; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart - Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Journal: BMJ Medicine

    Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

    doi: 10.1136/bmjmed-2023-000651

    Figure Lengend Snippet: Proportional first incident use of glucagon-like peptide-1 receptor agonists as second line therapy after metformin in patients with established cardiovascular disease, and patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Center; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart - Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

    Techniques:

    Proportional first incident use of sodium-glucose Cctransporter 2 inhibitors as second line therapy after metformin in (A) patients with established cardiovascular disease, and (B) patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart–Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Journal: BMJ Medicine

    Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

    doi: 10.1136/bmjmed-2023-000651

    Figure Lengend Snippet: Proportional first incident use of sodium-glucose Cctransporter 2 inhibitors as second line therapy after metformin in (A) patients with established cardiovascular disease, and (B) patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart–Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

    Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

    Techniques: